# Tuberculosis Case Study

**URL:** <https://www.medboundhub.com/t/tuberculosis-case-study/1859>\
**Category:** MBBS\
**Created:** [May 20, 2025, 4:28pm UTC](https://www.medboundhub.com/t/tuberculosis-case-study/1859 "2025-05-20T16:28:53Z")\
**Posts on this page:** 3\
**Page:** 1

<div class="post-metadata">

**Author:** ![Aadish](https://yyz1.discourse-cdn.com/flex033/user_avatar/www.medboundhub.com/aadish/32/308_2.png) [@Aadish](https://www.medboundhub.com/u/Aadish)\
**Post date:** [May 20, 2025, 4:28pm UTC](https://www.medboundhub.com/t/tuberculosis-case-study/1859/1 "2025-05-20T16:28:53Z")

</div>

A 30-year-old male patient, recently diagnosed with pulmonary tuberculosis, has been on standard antitubercular therapy (ATT) consisting of isoniazid, rifampicin, pyrazinamide, and ethambutol for 2 months. His sputum smear microscopy shows persistent positivity for acid-fast bacilli. The patient’s symptoms, such as cough and fever, have not significantly improved. What would be the next step in managing this patient’s treatment?

---

<div class="post-metadata">

**Author:** ![Moksha\_s](https://yyz1.discourse-cdn.com/flex033/user_avatar/www.medboundhub.com/moksha_s/32/271_2.png) [@Moksha\_s](https://www.medboundhub.com/u/Moksha_s)\
**Post date:** [May 20, 2025, 4:44pm UTC](https://www.medboundhub.com/t/tuberculosis-case-study/1859/2 "2025-05-20T16:44:48Z")

</div>

He might be resistant to these drugs so antimicrobial susceptibility test should be performed and regimen should be updated accordingly.

---

<div class="post-metadata">

**Author:** ![Adwaitha](https://yyz1.discourse-cdn.com/flex033/user_avatar/www.medboundhub.com/adwaitha/32/288_2.png) [@Adwaitha](https://www.medboundhub.com/u/Adwaitha)\
**Post date:** [May 20, 2025, 4:47pm UTC](https://www.medboundhub.com/t/tuberculosis-case-study/1859/3 "2025-05-20T16:47:00Z")

</div>

•Check TB is drug resistent as no cure after 2 months.  
•Conduct drug sensitivity.  
•Conveys which drug is sensitive and which one is resistive.  
•According to it give the drug to patient and monitor.  
•Follow-up treatment.
